Seqens and Pleryon Collaborate on GMP Polymer for Osteoarthritis Treatment

18 January 2024

Polymers Biobased & Circular Pharma CDMO Specialties Seqens Pleryon France

At a glance

SEQENS will produce Pleryon's polymer at its Aramon, France cGMP plant.
The Aramon site received a €15 million investment for modernization.
The new facility will be completed by Q2 2024.
The plant will support polymers for nucleic acid delivery and medical devices.

Collaboration Overview

Pleryon, a biotech startup, and SEQENS, a global player in pharmaceutical solutions, have partnered to develop and manufacture an innovative polymer for osteoarthritis treatment. SEQENS was selected for its extensive experience in polymer development.

Manufacturing Details

SEQENS will produce the custom polymer at its cGMP plant in Aramon, France. This site has been modernized with a €15 million investment to enhance its capabilities.

Facility Upgrade

The upgraded facility, set to be completed by Q2 2024, will support new GMP capabilities and technologies. It will cater to the growing demand for polymers in nucleic acid delivery, controlled-release excipients, prodrugs, and medical devices.